# Quantum Genesis AI Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Quantum Genesis AI Corp.). ## Overview Quantum Genesis AI Corp. is a U.S.-based development-stage biotechnology and industrial chemistry company focused on engineered enzymes for biotransformation and sustainable chemical manufacturing. Its work centers on applying quantum mechanics, molecular modeling, and enzyme engineering to improve chemical processes for pharmaceutical and other specialty-chemicals applications. ## Products & services • Engineered enzymes for active pharmaceutical ingredient production • Biotransformation solutions for cleaner chemical manufacturing • Enzyme design using quantum mechanics and molecular modeling • R&D for fragrance, flavors, and sustainable materials applications • Enzyme-based approaches for plastic degradation and carbon capture - **Engineered enzymes** (60%) — Custom-designed enzymes intended to improve selectivity, activity, and specificity in chemical processes. - **API biotransformation applications** (25%) — Enzyme-based process tools for active pharmaceutical ingredient manufacturing. - **Sustainable chemistry R&D** (15%) — Research programs aimed at extending enzyme platforms into green chemistry use cases. - Engineered enzymes for active pharmaceutical ingredient production - Biotransformation solutions for cleaner chemical manufacturing - Enzyme design using quantum mechanics and molecular modeling - R&D for fragrance, flavors, and sustainable materials applications - Enzyme-based approaches for plastic degradation and carbon capture ## Customers The company’s target customers are pharmaceutical manufacturers and other chemical producers that need more selective, step-efficient synthesis routes. It also aims to serve specialty-chemicals users in fragrances, flavors, sustainable materials, plastic degradation, and carbon capture applications. In practice, customers would buy the company’s enzyme technology to reduce process complexity, improve specificity, and support cleaner manufacturing. - **Pharmaceutical API manufacturers** (primary) — Buy engineered enzymes to support active pharmaceutical ingredient production and improve process selectivity. - **Specialty chemical producers** (secondary) — Use enzyme platforms for cleaner, more efficient manufacturing in fragrances, flavors, and related chemistries. - **Sustainability-focused industrial users** (emerging) — Explore enzyme applications in plastic degradation, carbon capture, and sustainable materials. - **Strategic partners and licensors** (primary) — May fund development, provide scale-up support, or commercialize the technology through alliances. - Pharmaceutical manufacturers seeking API process improvements - Chemical companies needing cleaner synthesis routes - Fragrance and flavor producers using specialty biocatalysts - Sustainable materials developers exploring enzyme applications - Potential strategic partners funding or commercializing the platform ## Geography The company is headquartered in San Diego, California, and its disclosed operations are U.S.-based. Its business model is not tied to a broad manufacturing footprint; instead, it relies on research, third-party testing facilities, and contract manufacturers for scale-up and enzyme production. Geography matters mainly through access to scientific talent, testing infrastructure, and outsourced manufacturing capacity. - Headquartered in San Diego, California - Primary operations are research and development in the United States - Uses third-party testing facilities on an as-needed basis - Depends on contract manufacturers for larger-scale enzyme production - No country-level revenue disclosure because the company has no revenue ## Strategy The company’s strategy is to advance engineered-enzyme technology from research into commercial use, starting with pharmaceutical API applications and then extending into adjacent specialty-chemicals markets. It also seeks strategic partnerships and outside financing to support development, scale-up, and broader commercialization. Building a scientific advisory capability and securing manufacturing/testing access are important to turning the platform into a repeatable business. - **Commercialize enzyme platforms in API production** (short-term) — Initial market focus provides a clear industrial use case and validation path for the technology. - **Expand into adjacent specialty-chemicals markets** (medium-term) — Fragrances, flavors, and sustainable chemistry broaden the addressable market beyond pharma. - **Establish strategic alliances and advisory depth** (medium-term) — Partnerships and scientific oversight can improve credibility, access, and commercialization speed. - Advance engineered enzymes from R&D into commercial deployment - Start with API manufacturing applications before expanding outward - Pursue partnerships to accelerate validation and commercialization - Build scientific advisory support around chemistry and biochemistry - Secure testing and manufacturing capacity for scale-up ## Risks The business is highly dependent on external funding, because it is still in development and has not generated revenue. Execution risk is elevated because enzyme scale-up depends on third-party manufacturers and testing facilities, while regulatory and intellectual-property dynamics can materially affect adoption in pharmaceutical and chemical markets. - **Funding shortfall** [critical] — The company has no firm financing arrangements and needs capital to continue development. - **Third-party manufacturing dependence** [high] — Large-scale enzyme production is outsourced, creating supply, timing, and quality exposure. - **Testing facility access constraints** [medium] — The company relies on off-site testing facilities without formal agreements. - **Regulatory and legal changes** [medium] — Biotransformation and chemical applications are exposed to evolving industry regulation. - **Key-person dependence** [high] — The company is early-stage and has a very small workforce, increasing reliance on a few individuals. - No revenue and dependence on external financing - Third-party manufacturing capacity and quality risk - Testing facility access can disrupt development timelines - Regulatory changes may affect biotech and chemical applications - Loss of key personnel could slow scientific execution ## Accounting As a development-stage company with no revenue, the most important accounting judgments relate to going concern assessment, financing transactions, and the valuation of equity issuances. Investors should also watch stock-based compensation, debt-related interest expense, and any future estimates tied to research assets or intangible technology acquired in transactions. - **Going concern** — Affects financial statement presentation and investor assessment of survival risk - **Equity issuance and dilution accounting** — Affects shareholders' equity and dilution analysis - **Stock-based compensation** — Can materially affect operating expenses - **Interest expense on debt** — Affects other expense and cash flow - Going concern assessment is central because operations are funded externally - Equity issuance valuation affects reported capital and expense recognition - Stock-based compensation can materially affect operating expenses - Debt and interest accounting matter as financing needs increase - Any acquired technology or intangibles would require valuation and impairment review --- *Last updated: 2026-04-29T04:50:43.643457+00:00*